220 related articles for article (PubMed ID: 31019002)
1. Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins.
Schepp RM; de Haan CAM; Wilkins D; Layman H; Graham BS; Esser MT; Berbers GAM
mSphere; 2019 Apr; 4(2):. PubMed ID: 31019002
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
4. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
5. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
6. Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.
Capella C; Chaiwatpongsakorn S; Gorrell E; Risch ZA; Ye F; Mertz SE; Johnson SM; Moore-Clingenpeel M; Ramilo O; Mejias A; Peeples ME
J Infect Dis; 2017 Dec; 216(11):1398-1406. PubMed ID: 29029312
[TBL] [Abstract][Full Text] [Related]
7. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age.
Jans J; Wicht O; Widjaja I; Ahout IM; de Groot R; Guichelaar T; Luytjes W; de Jonge MI; de Haan CA; Ferwerda G
PLoS One; 2017; 12(1):e0170877. PubMed ID: 28135305
[TBL] [Abstract][Full Text] [Related]
9. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
10. Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness.
Mazur NI; Horsley NM; Englund JA; Nederend M; Magaret A; Kumar A; Jacobino SR; de Haan CAM; Khatry SK; LeClerq SC; Steinhoff MC; Tielsch JM; Katz J; Graham BS; Bont LJ; Leusen JHW; Chu HY
J Infect Dis; 2019 Jan; 219(1):59-67. PubMed ID: 30107412
[TBL] [Abstract][Full Text] [Related]
11. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.
Piedra PA; Jewell AM; Cron SG; Atmar RL; Glezen WP
Vaccine; 2003 Jul; 21(24):3479-82. PubMed ID: 12850364
[TBL] [Abstract][Full Text] [Related]
12. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
McGinnes Cullen L; Schmidt MR; Morrison TG
J Virol; 2019 May; 93(9):. PubMed ID: 30760576
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
Chen Z; Zhang L; Tang A; Callahan C; Pristatsky P; Swoyer R; Cejas P; Nahas D; Galli J; Cosmi S; DiStefano D; Hoang VM; Bett A; Casimiro D; Vora KA
PLoS One; 2016; 11(6):e0156798. PubMed ID: 27258388
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
15. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
16. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
17. Serological Array-in-Well Multiplex Assay Reveals a High Rate of Respiratory Virus Infections and Reinfections in Young Children.
Kazakova A; Kakkola L; Päkkilä H; Teros-Jaakkola T; Soukka T; Peltola V; Waris M; Julkunen I
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511367
[TBL] [Abstract][Full Text] [Related]
18. Clinical Potential of Prefusion RSV F-specific Antibodies.
Rossey I; McLellan JS; Saelens X; Schepens B
Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
[TBL] [Abstract][Full Text] [Related]
20. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal.
Chu HY; Tielsch J; Katz J; Magaret AS; Khatry S; LeClerq SC; Shrestha L; Kuypers J; Steinhoff MC; Englund JA
J Clin Virol; 2017 Oct; 95():90-95. PubMed ID: 28903080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
